Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

Clover Health Investments, Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WILMINGTON, DEL., AUG. 31, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES: INTERIM CHIEF FINANCIAL OFFICER, CLAY THORNTON, WILL PRESENT AT THE 2026 JEFFERIES HEALTHCARE SERVICES AND TECHNOLOGY CONFERENCE ON TUESDAY, SEPTEMBER 15, 2026, AT 1:40 P.M.

CLOVER HEALTH TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

BUSINESS HIGHLIGHTS: DELIVERED STRONG SECOND QUARTER 2026 GAAP NET INCOME ALONGSIDE CONTINUED MARKET-LEADING MEDICARE ADVANTAGE MEMBERSHIP GROWTH IMPROVED FULL YEAR 2026 GUIDANCE ACROSS ALL METRICS INCREASING CONFIDENCE FOR 2027 OUTLOOK, SUPPORTED BY STRONG COHORT DEVELOPMENT, CONTINUED CLINICAL ENGAGEMENT, AND THE ADDED FLEXIBILITY OF A 4.5 STAR PAYMENT YEAR FINANCIAL RESULTS: SECOND QUARTER 2026 GAAP NET INCOME OF $28 MILLION, AN IMPROVEMENT OF $39 MILLION YEAR-OVER-YEAR SECOND QUARTER 2026 MEDICARE ADVANTAGE MEMBERSHIP OF 157,309, UP 48% YEAR-OVER-YEAR, AND TOTAL REVENUES OF $743 MILLION, UP 56% YEAR-OVER-YEAR SECOND QUARTER 2026 CONSOLIDATED GROSS PROFIT OF $153 MILLION, UP 54% YEAR-OVER-YEAR, AND ADJUSTED EBITDA OF $41 MILLION, UP 139% YEAR-OVER-YEAR IMPROVED FULL YEAR 2026 GUIDANCE: AVERAGE MEDICARE ADVANTAGE MEMBERSHIP OF 156,000 - 158,000, REPRESENTING 47% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT TOTAL REVENUES BETWEEN $2.92BILLION AND $3.00BILLION, REPRESENTING 54% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT CONSOLIDATED GROSS PROFIT BETWEEN $525MILLION AND $555MILLION, REPRESENTING 52% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT ADJUSTED EBITDA PROFITABILITY BETWEEN $70MILLION AND $85MILLION GAAP NET INCOME BETWEEN $20 MILLION AND $35 MILLION WILMINGTON, DEL., AUG. 05, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER 2026.

CLOVER HEALTH REPORTS SECOND QUARTER 2026 RESULTS

WILMINGTON, DEL., JULY 22, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY ANNOUNCED THAT ITS INTERIM CHIEF FINANCIAL OFFICER, CLAY THORNTON, WILL PRESENT AT THE 2026 CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE ON TUESDAY, AUGUST 11, 2026, AT 8:30 A.M.

CLOVER HEALTH TO PARTICIPATE IN UPCOMING CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE

WILMINGTON, DEL., JULY 09, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS AFTER THE MARKET CLOSES ON WEDNESDAY, AUGUST 5, 2026.

CLOVER HEALTH TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 5, 2026

SAN FRANCISCO, JULY 07, 2026 (GLOBE NEWSWIRE) -- COUNTERPART HEALTH,INC. (COUNTERPART), A WHOLLY OWNED SUBSIDIARY OF CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ:CLOV) (CLOVER OR CLOVERHEALTH), AND A LEADING AI-POWERED PHYSICIAN ENABLEMENT PLATFORM, TODAY RELEASED FINDINGS WITHIN THE WHITEPAPER CLINICAL EXCELLENCE IN CONTINUITY OF CARE: A REAL-WORLD ANALYSIS OF COUNTERPART ASSISTANT'S ROLE IN POST-HOSPITALIZATION FOLLOW-UP. THE WHITEPAPER EXAMINES THE RELATIONSHIP BETWEEN CA USE BY PRIMARY CARE PHYSICIANS (PCPS) AND PERFORMANCE ON HIGH-RISK CARE TRANSITION OUTCOMES, INCLUDING TWO HEDIS1 QUALITY MEASURES WITHIN CLOVER HEALTH'S MEDICARE ADVANTAGE POPULATION: TRANSITIONS OF CARE (TRC) AND FOLLOW-UP AFTER EMERGENCY DEPARTMENT VISIT FOR PEOPLE WITH MULTIPLE HIGH-RISK CHRONIC CONDITIONS (FMC).

CLINICAL EXCELLENCE IN CONTINUITY OF CARE: COUNTERPART ASSISTANT (CA) USE ASSOCIATED WITH STRONGER PERFORMANCE ACROSS TRANSITIONS OF CARE MEASURES AND POST-HOSPITALIZATION FOLLOW-UP

BUSINESS HIGHLIGHTS: DELIVERED POSITIVE GAAP NET INCOME IN THE FIRST QUARTER OF 2026, WITH STRONG PERFORMANCE ACROSS KEY METRICS: TOTAL REVENUES, ADJUSTED EBITDA, AND CONSOLIDATED GROSS PROFIT MARKET-LEADING MEDICARE ADVANTAGE MEMBERSHIP GROWTH WITH UNDERLYING TRENDS TRACKING IN LINE WITH EXPECTATIONS EXPECT TO MEET OR EXCEED FULL YEAR 2026 OUTLOOK ACROSS ALL METRICS, INCLUDING ACHIEVING FIRST FULL YEAR GAAP NET INCOME PROFITABILITY FINANCIAL RESULTS: FIRST QUARTER 2026 GAAP NET INCOME OF $27 MILLION, AN IMPROVEMENT OF $29 MILLION YEAR-OVER-YEAR FIRST QUARTER 2026 MEDICARE ADVANTAGE MEMBERSHIP OF 155,773, UP 51% YEAR-OVER-YEAR, AND TOTAL REVENUES OF $749 MILLION, UP 62% YEAR-OVER-YEAR FIRST QUARTER 2026 CONSOLIDATED GROSS PROFIT OF $160 MILLION, UP 47% YEAR-OVER-YEAR, AND ADJUSTED EBITDA OF $40 MILLION, UP 56% YEAR-OVER-YEAR FULL YEAR 2026 GUIDANCE: AVERAGE MEDICARE ADVANTAGE MEMBERSHIP OF 154,000 - 158,000, REPRESENTING 46% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT TOTAL REVENUES BETWEEN $2.81BILLION AND $2.92BILLION, REPRESENTING 49% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT CONSOLIDATED GROSS PROFIT BETWEEN $470MILLION AND $510MILLION, REPRESENTING 38% GROWTH YEAR-OVER-YEAR AT THE MIDPOINT ADJUSTED EBITDA PROFITABILITY BETWEEN $50MILLION AND $70MILLION GAAP NET INCOME BETWEEN $0 MILLION AND $20 MILLION WILMINGTON, DEL., MAY 06, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER 2026.

CLOVER HEALTH REPORTS FIRST QUARTER 2026 RESULTS

WILMINGTON, DEL., APRIL 08, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS AFTER THE MARKET CLOSES ON WEDNESDAY, MAY 6, 2026.

CLOVER HEALTH TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 6, 2026

WILMINGTON, DEL., APRIL 07, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER, CLOVER HEALTH OR THE COMPANY), A PHYSICIAN ENABLEMENT COMPANY COMMITTED TO BRINGING ACCESS TO GREAT HEALTHCARE TO EVERYONE ON MEDICARE, IN PARTNERSHIP WITH HEALTHEX , TODAY ANNOUNCED A NEW COLLABORATION THAT ENABLES CLOVER MEDICARE ADVANTAGE (MA) MEMBERS TO SECURELY ACCESS AND SHARE CLINICAL RECORDS AND CLAIMS DATA, FURTHER ADVANCING PATIENTS RIGHTS TO ACCESS AND SHARE THEIR OWN HEALTH DATA, WHICH IS CENTRAL TO FEDERAL INTEROPERABILITY EFFORTS.

CLOVER HEALTH EMPOWERS MEMBERS TO TAKE CHARGE OF THEIR HEALTH DATA THROUGH HEALTHEX PARTNERSHIP

WILMINGTON, DEL., APRIL 01, 2026 (GLOBE NEWSWIRE) -- CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ: CLOV) (CLOVER OR THE COMPANY), A PHYSICIAN ENABLEMENT COMPANY COMMITTED TO BRINGING ACCESS TO GREAT HEALTHCARE TO EVERYONE ON MEDICARE, TODAY ANNOUNCED THAT PETER KUIPERS IS STEPPING DOWN AS THE CHIEF FINANCIAL OFFICER OF THE COMPANY, EFFECTIVE MARCH 30, 2026. MR. KUIPERS WILL REMAIN WITH THE COMPANY IN AN ADVISORY CAPACITY THROUGH APRIL 24, 2026 TO SUPPORT A SMOOTH TRANSITION AND HANDOFF. MR. KUIPERS AND THE COMPANY NOTED THAT HIS DEPARTURE DOES NOT REFLECT ANY DISAGREEMENT WITH THE COMPANY ON ANY MATTER RELATING TO THE COMPANY'S OPERATIONS, POLICIES OR PRACTICES.

CLOVER HEALTH ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICER; REITERATES MOST RECENTLY ISSUED FINANCIAL GUIDANCE FOR FULL FISCAL YEAR 2026

SAN FRANCISCO, MARCH 19, 2026 (GLOBE NEWSWIRE) -- COUNTERPART HEALTH,INC. (COUNTERPART), A WHOLLY OWNED SUBSIDIARY OF CLOVER HEALTH INVESTMENTS, CORP. (NASDAQ:CLOV) (CLOVER, CLOVERHEALTH OR THE COMPANY), AND A LEADING AI-POWERED PHYSICIAN-ENABLEMENT PLATFORM TODAY RELEASED A WHITEPAPER TITLED DRIVING CLINICAL EXCELLENCE IN CHRONIC DISEASE: COUNTERPART ASSISTANT'S ROLE IN FLU PREVENTATIVE CARE. THE ANALYSIS EXAMINES THE ROLE OF CA'S REAL-TIME CLINICAL INSIGHTS ON IMMUNIZATION RATES AND FLU-RELATED ACUTE CARE UTILIZATION WITHIN CLOVER HEALTH'S MEDICARE ADVANTAGE (MA) POPULATION.

Clover Health Investments, Corp.

CLOV

Price

Financial Reports

No items found.

Press Releases

Clover Health Investments, Corp.

CLOV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CLOV